Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation

Clinical and Applied Thrombosis/Hemostasis

Volumn 22, Issue 5, 2016, Pages 476-482

  Canpolat, Ugur ^a   Çetin, Elif Hande ^a   Cetin, Serkan ^a   Aydin, Selahattin ^a   Akboga, Mehmet Kadri ^a   Yayla, Cagri ^a   Turak, Osman ^a   Aras, Dursun ^a   Aydogdu, Sinan ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

coronary slow flow; high density lipoprotein cholesterol; inflammation; monocyte count

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOHEXOL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UREA; BIOLOGICAL MARKER;

ADULT; ANGIOGRAPHY DEVICE; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CREATININE BLOOD LEVEL; DIGITAL SUBTRACTION ANGIOGRAPHY; FEMALE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYOCARDIAL INFARCTION FRAME COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SYSTEMIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; BLOOD CELL COUNT; BLOOD FLOW VELOCITY; CASE CONTROL STUDY; CYTOLOGY; MIDDLE AGED; NO REFLOW PHENOMENON; OXIDATIVE STRESS;

AGED; BIOMARKERS; BLOOD CELL COUNT; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY CIRCULATION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MONOCYTES; NO-REFLOW PHENOMENON; OXIDATIVE STRESS; RETROSPECTIVE STUDIES;

EID: 84973151909     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029615594002     Document Type: Article

References (23)

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E,. Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding. Am Heart J. 1972; 84 (1): 66-71.
2. Goel PK, Gupta SK, Agarwal A, Kapoor A,. Slow coronary flow: a distinct angiographic subgroup in syndrome X. Angiology. 2001; 52 (8): 507-14.
3. Erdogan D, Caliskan M, Gullu H, Sezgin AT, Yildirir A, Muderrisoglu H,. Coronary flow reserve is impaired in patients with slow coronary flow. Atherosclerosis. 2007; 191 (1): 168-174.
4. Barutcu I, Sezgin AT, Sezgin N, et al. Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow. Angiology. 2007; 58 (4): 401-407.
5. Enli Y, Turk M, Akbay R, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther. 2008; 25 (1): 37-44.
6. Kalay N, Aytekin M, Kaya MG, et al. The relationship between inflammation and slow coronary flow: increased red cell distribution width and serum uric acid levels. Turk Kardiyol Dern Ars. 2011; 39 (6): 463-468.
7. Mosseri M, Yarom R, Gotsman MS, Hasin Y,. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986; 74 (5): 964-972.
8. Sezgin AT, Sigirci A, Barutcu I, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003; 14 (2): 155-161.
9. Xu Y, Meng HL, Su YM, et al. Serum YKL-40 is increased in patients with slow coronary flow. Coron Artery Dis. 2015; 26 (2): 121-125.
10. Ancuta P, Wang J, Gabuzda D,. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol. 2006; 80 (5): 1156-1164.
11. Hessler JR, Robertson AL Jr, Chisolm GM III,. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis. 1979; 32 (3): 213-229.
12. Li XP, Zhao SP, Zhang XY, Liu L, Gao M, Zhou QC,. Protective effect of high density lipoprotein on endothelium-dependent vasodilatation. Int J Cardiol. 2000; 73 (3): 231-236.
13. Parthasarathy S, Barnett J, Fong LG,. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990; 1044 (2): 275-283.
14. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014; 46 (8): 1619-1625.
15. Li JJ, Qin XW, Li ZC, et al. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta. 2007; 385 (1-2): 43-47.
16. Wang X, Geng LL, Nie SP,. Coronary slow flow phenomenon: a local or systemic disease? Med Hypotheses. 2010; 75 (3): 334-337.
17. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E,. Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol. 2013; 62 (17): 1541-1551.
18. Murphy AJ, Chin-Dusting JP, Sviridov D, Woollard KJ,. The anti inflammatory effects of high density lipoproteins. Curr Med Chem. 2009; 16 (6): 667-675.
19. Murphy AJ, Woollard KJ,. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010; 37 (7): 710-718.
20. Yvan-Charvet L, Pagler T, Gautier EL, et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science. 2010; 328 (5986): 1689-1693.
21. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH,. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002; 144 (1): 165-172.
22. Kuvin JT, Patel AR, Sidhu M, et al. Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol. 2003; 92 (3): 275-279.
23. Turhan H, Saydam GS, Erbay AR, et al. Increased plasma soluble adhesion molecules; ICAM-1, VCAM-1, and E-selectin levels in patients with slow coronary flow. Int J Cardiol. 2006; 108 (2): 224-230.